ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2004
Evidence from biomarkers and surrogate endpoints.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pathologic Complete Response and Survival in Rectal Cancer: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Trial
- A Comparison of 11 Clinical Risk Scores for Prediction of Survival After Curative-Intent Resection of Colorectal Liver Metastases.Annals of surgical oncology · 2026Article
- Endpoint selection and evaluation in hematology studies.Best practice & research. Clinical haematology · 2023Review
- Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases.Pharmaceutics · 2023Review
- Clinical endpoints in oncology - a primer.American journal of cancer research · 2021Review
- The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.Oncotarget · 2016Review
- Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.Molecular diagnosis & therapy · 2011Article
- The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).The journal of nutrition, health & aging · 2009Review
- Thalamic metabolism and symptom onset in preclinical Huntington's disease.Brain : a journal of neurology · 2007Article
- Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.CNS drugs · 2007Review
- Biomarkers in chronic adult hydrocephalus.Cerebrospinal fluid research · 2006Article
- Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of physiological, anatomical, and other biological tests is commonplace in the practice of medicine. In neurology, objectively measured tests termed biomarkers (BMs) are playing an increasing role in diagnosis and management of disease, both in clinical practice and in experimental therapeutics. This article will discuss the various applications of BMs to the assessment of therapies for neurological diseases and will use examples from neurological diseases to elucidate the strengths and potential weaknesses of BMs. As the understanding of the pathophysiology of many neurological diseases has improved, new BMs have been developed, and efforts have been made to use these as proxies for clinical endpoints. A BM used in this manner is referred to as a surrogate endpoint (SE). There are many potential advantages and disadvantages of using SEs in the evaluation of new therapies, and these will be reviewed as well. Furthermore, the evidence required for the development of an SE and the nature of the evidence that can be derived from the use of BMs and SEs will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.